Eisai temporarily withdraws cancer drug NDA in China

28 June 2017

Japanese drug major Eisai (TYO: 4523) has said that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for its anticancer agent Halaven (eribulin mesylate) in China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Biotechnology

European approval for Eisai's Halaven for advanced liposarcoma

5 May 2016

Biotechnology

Eisai's Halaven shows survival benefit in metastatic soft tissue sarcoma in new study

1 August 2016

Pharmaceutical

Eisai and PIQUR team up for breast cancer drug trials

17 February 2016

Pharmaceutical

IQWiG's negative view on Halaven bewilders Eisai

5 September 2016

Companies featured in this story

More ones to watch >

Company Spotlight

BeOne Medicines

A Nasdaq-listed oncology biotechnology company developing and commercializing cancer therapies across hematologic malignancies and solid tumors. BeOne Medicines operates a global development and commercial platform spanning North America, Europe and Asia.